Novartis scores 1 point higher than Roche Holding on SINK's sustainability index.
Novartis is more sustainable according to SINK's open sustainability index, scoring 50/100 vs Roche Holding's 49/100 — a difference of 1 points.
Novartis scores 50/100 on the SINK sustainability index (Making progress). Novartis demonstrates solid operational decarbonization and supply-chain engagement but relies heavily on carbon credits for claimed neutrality. Nature strategy is nascent. A 2022 NGO assessment flagged 'very low integrity' targets—since partially addressed by SBTi validation—and the company retains trade association memberships with poor climate records.
Roche Holding scores 49/100 on the SINK sustainability index (Making progress). Roche has achieved strong operational decarbonisation (46% S1&2 reduction since 2022) and received SBTi validation for net-zero targets — a pharma first. However, nature and biodiversity assessment remains absent, water targets lack absolute reduction commitments, and significant non-environmental regulatory penalties ($433M since 2000) persist alongside VCI trade association misalignment.
Both companies are rated on the same 10-question SINK rubric: Scope 1/2/3 carbon footprint, energy source, nature and biodiversity, resource use, water, emissions trajectory, science-based targets, transparency, and controversies. Scores are 0–100, based on public data, and fully reproducible.
See the full leaderboard — 500+ companies ranked.
View full leaderboard →